Pharma & Bio
Technology
“Phase 2b Isn’t Mandatory”… Will Kangstem Biotech’s Strategy of Speeding Through Clinical Trials Pay Off?
Bae Yo-han, Head of Clinical Development at Kangstem Biotech, is presenting at a briefing on the results of the Phase 2a clinical trial for “OSCA,” held on the 29th at the FKI Tower in Yeouido, Seoul.…
Technology
Exchange Rates Driven by CMO, Patent Cliffs by Biosimilars… Promising Sectors Amid the Recession
While the biotech industry is experiencing an overall slowdown in investment and a funding crunch, forecasts suggest that contract manufacturing organizations (CMOs) and contract development and manuf…
Technology
Novartis Moves Beyond Obesity to Lead in MASH… Why Is It Collecting Non-Invasive Data in Korea?
(Graphic: ChatGPT)
Danish pharmaceutical company Novo Nordisk has launched a large-scale real-world data study using medical records from approximately 10,000 patients in South Korea with metaboli…
Technology
[The Era of Oral Obesity Drugs, Part 2] Big Pharma vs. K-Bio: The Battle Grounds Are 'Price' and 'Formulation Innovation'
As the era of “oral” GLP-1 therapies officially begins in the global obesity treatment market, observers are suggesting that K-Bio companies may need to rethink their survival strategies. This is beca…
Lifestyle
Mezzion Pharma Co., Ltd. Simultaneously Improves Cysts and Kidney Function in ADPKD… “Moving Directly to Phase 2b Clinical Trials in Korea and the U.S.”
“When you examine the kidneys of mice with polycystic kidney disease, you can see large cysts. However, after administering Udenafil, a reduction in the size of these cysts was visible even to the nak…
Technology
Onconic Surges on Jaqbo’s Approval in India [K-Bio Pulse]
South Korea’s pharmaceutical and life sciences sectors rose in tandem on Aug. 6, led by Onconic Therapeutics, Qurient, and Voronoi.The pharmaceutical index gained 2.24%, with 97 of 161 stocks closing …
Lifestyle
Onconic Soars on Jakuvo Approval in India… Qurient Co., Ltd. and Voronoi, Inc. Also Gain Ground [Bio Spotlight]
On the 6th, the pharmaceutical and life sciences sectors rose in tandem on the domestic stock market. The pharmaceutical sector rose 2.24% from the previous trading day. Of the 161 stocks in the secto…
Lifestyle
[Expert Insight] Min Kyung-jun, Director of Newmin Hospital: “The Paradigm in Joint Treatment Is Shifting Toward ‘Conservation’… Keep an Eye on CartiLife”
“Knee cartilage lacks blood vessels, so once damaged, it is difficult to recover naturally. Rather than enduring the pain, it is important to accurately diagnose the extent of the damage and choose a …
Lifestyle
“Human Hair Follicles Regrew”… Orient Bio’s OND-1 Is 10 Times More Effective Than Minoxidil in Treating Hair Loss
“We shouldn’t make claims about a new hair-growth drug based solely on a photo showing hair growing on a mouse’s back. The key is how much lower the concentration is compared to existing treatments, a…
Lifestyle
D&D Pharmatech Plummets 18% After Pfizer Halts ORALINK Candidate [K-bio pulse]
D&D Pharmatech shares fell sharply after it was confirmed that development had been halted on an obesity drug candidate built using the company’s technology. Coming on the heels of questions about Pep…